Entrectinib gets edge over crizotinib against ROS1+ lung cancer - Medical Xpress

Entrectinib gets edge over crizotinib against ROS1+ lung cancer  Medical Xpress

Crizotinib and entrectinib are both active against ROS1+ non-small cell lung cancer. But which is best? The answer seems easy: Just compare the drugs' clinical ...